Published in Lancet on January 12, 2008
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care (2013) 4.85
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest (2011) 4.21
Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab (2009) 3.98
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet (2014) 3.94
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ (2011) 2.40
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM (2009) 2.14
Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg (2013) 2.05
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol (2011) 1.85
Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol (2011) 1.82
Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes (2012) 1.79
Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care (2011) 1.64
MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc (2012) 1.63
Treatment Options for Statin-Associated Muscle Symptoms. Dtsch Arztebl Int (2015) 1.55
Are statins diabetogenic? Curr Opin Cardiol (2011) 1.54
Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol (2011) 1.45
Diabetes and Cause-Specific Mortality in Mexico City. N Engl J Med (2016) 1.44
Strategies for prescribing statins. BMJ (2008) 1.41
Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr (2017) 1.39
Development and evaluation of an ensemble resource linking medications to their indications. J Am Med Inform Assoc (2013) 1.28
Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res (2011) 1.26
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol (2011) 1.19
Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol (2013) 1.18
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep (2012) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Hypertension in diabetes: a call to action. Can J Cardiol (2009) 1.10
Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. World J Diabetes (2013) 1.10
Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol (2010) 1.07
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment. Circ Cardiovasc Qual Outcomes (2012) 1.06
Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr (2010) 1.05
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care (2009) 1.04
Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc (2013) 1.03
Abdominal obesity: the cholesterol of the 21st century? Can J Cardiol (2008) 1.03
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register. PLoS One (2011) 1.02
The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One (2008) 1.01
The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. Patient Prefer Adherence (2012) 1.01
Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. Cardiovasc Diabetol (2012) 1.01
Improving quality of care for persons with diabetes: an overview of systematic reviews - what does the evidence tell us? Syst Rev (2013) 1.00
Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract (2010) 0.99
Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol (2009) 0.99
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J (2012) 0.98
Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients. J Gen Intern Med (2016) 0.97
Stroke: morbidity, risk factors, and care in taiwan. J Stroke (2014) 0.95
Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud (2013) 0.95
Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovasc Diabetol (2011) 0.95
Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis (2010) 0.95
Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study. BMJ Open (2011) 0.94
Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes Metab J (2015) 0.94
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Are investments in disease prevention complements? The case of statins and health behaviors. J Health Econ (2014) 0.93
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol (2013) 0.93
Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol (2009) 0.92
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc Health Risk Manag (2009) 0.92
The lipid profile and mortality risk in elderly type 2 diabetic patients: a ten-year follow-up study (ZODIAC-13). PLoS One (2009) 0.92
Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. Ann Epidemiol (2014) 0.92
American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care (2009) 0.92
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud (2013) 0.91
Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Trans Am Clin Climatol Assoc (2011) 0.91
Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol (2008) 0.91
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol (2009) 0.91
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol (2010) 0.90
The vascular endothelium in diabetes--a therapeutic target? Rev Endocr Metab Disord (2013) 0.89
Glycemic control and cardiovascular disease: what's a doctor to do? Curr Diab Rep (2012) 0.89
Should all diabetic patients be treated with a statin? Diabetes Care (2009) 0.89
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol (2013) 0.89
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice? PLoS Med (2010) 0.89
Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. Diabetes Care (2009) 0.88
Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep (2010) 0.88
Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med (2013) 0.88
Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One (2014) 0.88
High density lipoprotein: a therapeutic target in type 2 diabetes. Endocrinol Metab (Seoul) (2013) 0.87
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc (2011) 0.87
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag (2009) 0.87
The causes and consequences of low levels of high density lipoproteins in patients with diabetes. Diabetes Metab J (2011) 0.86
Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. Indian Heart J (2015) 0.86
Safety of statins: an update. Ther Adv Drug Saf (2012) 0.86
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications (2014) 0.86
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS One (2012) 0.86
Accounting for clinical action reduces estimates of gender disparities in lipid management for diabetic veterans. J Gen Intern Med (2013) 0.85
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J (1976) 28.28
The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst (1981) 25.60
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ (1994) 23.80
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics (1973) 18.14
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
A long-term follow-up study of women using different methods of contraception--an interim report. J Biosoc Sci (1976) 13.09
The natural history of chronic airflow obstruction. Br Med J (1977) 13.04
Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet (2004) 12.59
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ (1998) 10.71
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med (1997) 8.25
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health (1978) 7.80
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet (2015) 7.29
UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet (2000) 7.19
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ (1994) 6.74
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (2008) 6.67
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ (1998) 6.13
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.50
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Mortality in relation to smoking: 22 years' observations on female British doctors. Br Med J (1980) 5.21
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08
The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis (1983) 4.90
Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst (2004) 4.83
Mortality among doctors in different occupations. Br Med J (1977) 4.60
Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. BMJ (1998) 4.51
Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol (1994) 4.50
Sudden fall in breast cancer death rates in England and Wales. Lancet (1995) 4.50
Can dietary beta-carotene materially reduce human cancer rates? Nature (1981) 4.43
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Tobacco--the growing epidemic. Nat Med (1999) 4.31
Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA (1997) 4.09
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet (2001) 3.71
Fundamental carcinogenic processes and their implications for low dose risk assessment. Cancer Res (1976) 3.58
Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol (1995) 3.51
Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ (1997) 3.51
Why do we need systematic overviews of randomized trials? Stat Med (1987) 3.33
How often does surgery for peptic ulceration eradicate Helicobacter pylori? Systematic review of 36 studies. BMJ (1998) 3.10
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05